Xtant Medical Holdings (XTNT) Research & Development (2010 - 2025)

Xtant Medical Holdings (XTNT) has 16 years of Research & Development data on file, last reported at $634000.0 in Q3 2025.

• On a quarterly basis, Research & Development fell 9.56% year-over-year to $634000.0 in Q3 2025; TTM through Sep 2025 was -$11.7 million, a 146.06% decrease from a year earlier, with the FY2024 full-year figure at $2.4 million, down 93.8% from the prior year.
• Research & Development for Q3 2025 stood at $634000.0, down from $11.6 million in the prior quarter.
• Over the last five years, Research & Development for XTNT reached as high as $21.8 million in Q4 2022 and fell as low as -$35.1 million in Q4 2024.
• Historically, Research & Development has averaged $3.9 million across 5 years, with a median of $5.2 million in 2022.
• Across the five-year window, Research & Development jumped 14358.28% in 2022 and slumped 403.39% in 2024, its largest moves.
• Year by year, Research & Development stood at $151000.0 in 2021, then soared by 14358.28% to $21.8 million in 2022, then tumbled by 46.94% to $11.6 million in 2023, then slumped by 403.39% to -$35.1 million in 2024, then jumped by 101.8% to $634000.0 in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $634000.0 in Q3 2025, $11.6 million in Q2 2025, and $11.2 million in Q1 2025.